A new study shows that chimeric antigen receptor T cells produce objective responses in 71% of patients with chronic lymphocytic leukemia whose disease progressed despite receiving ibrutinib or who are unable to tolerate the drug. Cancer cells were undetectable in the bone marrow in 81% of tested patients, and 64% of tested patients showed complete lymph node responses. Most patients experienced adverse effects, however.
from Cancer via ola Kala on Inoreader http://ift.tt/2wuhzgE
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου